DUKE Robotics Corp. 8-K

What Happened

• DUKE Robotics Corp. announced on May 14, 2026 that it entered an underwriting agreement with Maxim Group LLC for a public offering of 1,125,000 units, each unit consisting of one share of common stock and one warrant to buy one share. The combined public offering price was $8.20 per unit.
• The warrants issued with the units have an $8.60 exercise price and a five‑year term (subject to adjustments and cashless exercise provisions). The underwriters had a 45‑day over‑allotment option for up to 168,750 additional shares/warrants; the underwriter partially exercised that option for 168,750 warrants on May 15, 2026. The offering closed on May 18, 2026, producing approximately $9,225,000 in gross proceeds before fees and expenses.
• Concurrently, the company issued up to 90,000 representative’s warrants to the underwriter’s designee with a $10.25 exercise price, exercisable Nov 14, 2026 through Nov 14, 2031. The company also appointed Equiniti Trust Company LLC as warrant agent.

Key Details

• Offering size: 1,125,000 units at $8.20 per unit; aggregate gross proceeds ≈ $9,225,000 (before underwriting discounts/commissions and expenses).
• Warrant terms: exercise price $8.60, five‑year term; over‑allotment exercised for 168,750 warrants.
• Representative’s warrants: up to 90,000 shares, $10.25 exercise, exercisable 11/14/2026–11/14/2031.
• Uses of proceeds: research & development, sales expansion, marketing, business development, potential acquisitions and general working capital. Lock‑ups: 6‑month resale restrictions for the company’s officers, directors and certain shareholders; 18‑month right of first refusal granted to the underwriter for future offerings.

Why It Matters

• The offering provides DUKE Robotics with fresh capital to fund R&D and growth initiatives, which can support product development and market expansion.
• Existing shareholders face dilution from newly issued shares and outstanding warrants; further dilution could occur if warrants are exercised.
• The underwriter’s over‑allotment exercise, representative’s warrants and the 18‑month right of first refusal indicate ongoing underwriting relationships and potential costs/constraints for future capital raises.
• Net proceeds will be lower than the gross $9.225M after underwriting fees and expenses, so investors should watch future disclosures for precise use of funds and any impact on runway or capital needs.